*001441319
*00520191206072314.0
*007ta
*008140730s2019    no a   e m    00  0 eng
*00901393nam a2200313 c 4500
*019  $bl
*020  $a978-82-308-3557-9$qheftet
*035  $a(EXLNZ-47BIBSYS_NETWORK)999920815145602201
*035  $a(NO-LaBS)14720437(bibid)
*040  $aNO-OsNB$bnob$erda
*060 4$aWP 870
*08204$a616.99449061$223/nor$qNO-OsNB
*1001 $aHelland, Thomas$d1983-$0(NO-TrBIB)11081597$4aut$_73030500
*24510$aTamoxifen in the treatment of luminal breast cancer :$bimplications of active metabolites on gene expression, side effects and clinical outcome$cThomas Helland
*260  $a[Bergen]$bUniversity of Bergen$c2019
*300  $a1 bind (varierende paginering)$billustrasjoner$c24 cm
*336  $atekst$0http://rdaregistry.info/termList/RDAContentType/1020$2rdaco
*337  $auformidlet$0http://rdaregistry.info/termList/RDAMediaType/1007$2rdamt
*338  $abind$0http://rdaregistry.info/termList/RDACarrierType/1049$2rdact
*500  $aDelvis opptrykk av artikler
*502  $aAvhandling (ph.d.) - Universitetet i Bergen, 2019
*650 2$aBreast Neoplasms$xdrug therapy$0(DNLM)D001943Q000188$_25522900
*650 2$aBreast Neoplasms$xmortality$0(DNLM)D001943Q000401$_73030700
*650 2$aTamoxifen$0(DNLM)D013629$_73030800
*7102 $aUniversitetet i Bergen$0(NO-TrBIB)90063607$4pbl$_10049500
*7102 $aUniversitetet i Bergen$bKlinisk institutt 1$0(NO-TrBIB)13016704$4dgg$_11824000
*913  $aNorbok$bNB
*917  $ad
*999  $aoai:nb.bibsys.no:999919989993602202$b2021-12-08T03:25:10Z$z999919989993602202
^